Roche to Acquire 89bio in $3.5 Billion Deal to Expand Weight-Loss Portfolio
BASEL — Swiss pharmaceutical giant Roche has agreed to acquire U.S.-based biotech firm 89bio in a deal valued at up to $3.5 billion, marking a strategic move into the rapidly expanding weight-loss therapeutics market. The acquisition centers on 89bio’s lead candidate, pegozafermin, a novel compound in late-stage development for nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia—conditions […]
Continue Reading